Targeting glycolytic pathway with 2-Deoxy-glucose enhances lapatinib sensitivity in HER2-amplified breast cancer

被引：0
|
作者：
Chen, Xiaosong [1 ]
Liu, Junjun [1 ]
Ward, Toby [2 ]
Liu, Xiaofei [2 ]
Mao, Yan [1 ]
Bockhorn, Jessica [2 ]
Shen, Kunwei [1 ]
Pegram, Mark [2 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai 200030, Peoples R China
[2] Stanford Canc Inst, Stanford, CA USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-713
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
713
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2
    Guix, M.
    Aura, C. M.
    Jimenez, J.
    Scaltriti, M.
    Gomez, H. L.
    Doval, D. C.
    Ellis, C.
    Gagnon, R.
    Liu, Y.
    Koehler, M.
    Baselga, J.
    CANCER RESEARCH, 2009, 69 (02) : 100S - 100S
  • [2] Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
    Marcia R. Campbell
    Hui Zhang
    Shabnam Ziaee
    Ana Ruiz-Saenz
    Nathaniel Gulizia
    Julie Oeffinger
    Dhara N. Amin
    Deepika Ahuja
    Mark M. Moasser
    Catherine C. Park
    Breast Cancer Research and Treatment, 2016, 155 : 431 - 440
  • [3] Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
    Campbell, Marcia R.
    Zhang, Hui
    Ziaee, Shabnam
    Ruiz-Saenz, Ana
    Gulizia, Nathaniel
    Oeffinger, Julie
    Amin, Dhara N.
    Ahuja, Deepika
    Moasser, Mark M.
    Park, Catherine C.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 431 - 440
  • [4] A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer
    Gang Ning
    Qihui Zhu
    Wonyoung Kang
    Hamin Lee
    Leigh Maher
    Yun-Suhk Suh
    Michael Michaud
    Mayerlin Silva
    Jee Young Kwon
    Chengsheng Zhang
    Charles Lee
    BMC Cancer, 21
  • [5] A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer
    Ning, Gang
    Zhu, Qihui
    Kang, Wonyoung
    Lee, Hamin
    Maher, Leigh
    Suh, Yun-Suhk
    Michaud, Michael
    Silva, Mayerlin
    Kwon, Jee Young
    Zhang, Chengsheng
    Lee, Charles
    BMC CANCER, 2021, 21 (01)
  • [6] Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
    Leung, Wing-yin
    Roxanis, Ioannis
    Sheldon, Helen
    Buffa, Francesca M.
    Li, Ji-Liang
    Harris, Adrian L.
    Kong, Anthony
    ONCOTARGET, 2015, 6 (08): : 5678 - 5694
  • [7] Targeting HER 1 and 2 in breast cancer with lapatinib
    Higa, Gerald M.
    ONCOLOGY REVIEWS, 2008, 2 (01) : 21 - 28
  • [8] Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases
    Kodack, David P.
    Chung, Euiheon
    Yamashita, Hiroshi
    Incio, Joao
    Duyverman, Annique M. M. J.
    Song, Youngchul
    Farrar, Christian T.
    Huang, Yuhui
    Ager, Eleanor
    Kamoun, Walid
    Goel, Shom
    Snuderl, Matija
    Lussiez, Alisha
    Hiddingh, Lotte
    Mahmood, Sidra
    Tannous, Bakhos A.
    Eichler, April F.
    Fukumura, Dai
    Engelman, Jeffrey A.
    Jain, Rakesh K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (45) : E3119 - E3127
  • [9] Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside
    Tsang, Roger Y.
    Sadeghi, Saeed
    Finn, Richard S.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2011, 3 : 1 - 13
  • [10] MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
    Chen, Chin-Tung
    Kim, Hyaehwan
    Liska, David
    Gao, Sizhi
    Christensen, James G.
    Weiser, Martin R.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (03) : 660 - 669
12345